title: Effect of single post-ovulatory administration of levonorgestrel on gene expression profile during the receptive period of the human endometrium.
abstract: The hypothesis that levonorgestrel (LNG) used as an emergency contraceptive interferes with endometrial receptivity remains unproven. We compared the endometrial gene expression profile during the receptive period after administering a single dose of LNG 1.5 mg or placebo on day 1 of the luteal phase. An endometrial biopsy was done on day LH+7 or LH+8 and samples were taken from seven volunteers, each one contributing with one cycle treated with placebo and another with LNG. The expression of 20 383 genes was determined using cDNA microarrays. Real-time RT-PCR was used 1) to confirm the differences found in DNA microarray analysis and 2) to determine the effect of LNG on transcript levels of C3, C4BPα, COX2, MAOA, S100A4, and SERPINB9, known to be upregulated during receptivity, and on cPLA2α, JAK1, JNK1, CTSL1, and GSTP1, known to respond to mifepristone. Additional endometrial biopsies were done during the pre-receptive (LH+3) and receptive (LH+7) period and samples were taken from eight untreated volunteers in order to determine the changes associated with acquisition of receptivity of 14 genes. Mean levels of PAEP, TGM2, CLU, IGF2, and IL6ST mRNAs increased after administering LNG while those of HGD, SAT1, EVA1, LOC90133, ANXA1, SLC25A29, CYB5A, CRIP1, and SLC39A14 decreased. Except for the level of ANXA1 transcript, all changes remained within the range observed in untreated controls, and none of the transcripts responding to mifepristone changed in response to LNG. Post-ovulatory administration of LNG caused minimal changes in gene expression profiling during the receptive period. Neither the magnitude nor the nature or direction of the changes endorses the hypothesis that LNG interferes with endometrial receptivity.
authors: Universidad Santiago de Chile, Santiago, Chile.
authors: M F
authors: MF
authors: Vargas
authors: A A
authors: AA
authors: Tapia-Pizarro
authors: S P
authors: SP
authors: Henríquez
authors: M
authors: M
authors: Quezada
authors: A M
authors: AM
authors: Salvatierra
authors: G
authors: G
authors: Noe
authors: D J
authors: DJ
authors: Munroe
authors: L A
authors: LA
authors: Velasquez
authors: H B
authors: HB
authors: Croxatto
mesh_terms: D003271:Contraceptive Agents, Female / Q000008:administration & dosage / Q000494:pharmacology*; D004717:Endometrium / Q000187:drug effects* / Q000378:metabolism*; D005260:Female; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D016912:Levonorgestrel / Q000008:administration & dosage / Q000494:pharmacology*; D008183:Luteal Phase / Q000187:drug effects* / Q000235:genetics*; D008597:Menstrual Cycle / Q000187:drug effects / Q000502:physiology; D015735:Mifepristone / Q000494:pharmacology; D011374:Progesterone / Q000378:metabolism; D015203:Reproducibility of Results; D059467:Transcriptome / Q000187:drug effects
chemical_list: D003271:Contraceptive Agents, Female; D015735:Mifepristone; D011374:Progesterone; D016912:Levonorgestrel